Citations

Clear

219 citation(s) found for "Do, Ron".

A spatial transcriptomics atlas of live donors reveals unique zonation patterns in the healthy human liver
Yakubovsky, Oran , Egozi, Adi, Halpern, Keren Bahar , Barkai, Tal, Harnik, Yotam , Novoselsky, Roy , Goliand, Inna , Keren‐Shaul, Hadas , Hirsch, Dana , Mayer, Chen , Pery, Ron, Pencovich, Niv , Taner, Timucin, Nachmany, Ido , Afriat, Amichay , Kohanim, Yael Korem , Golani, Ofra , Addadi, Yoseph , Kedmi, Merav , Fellus-Alyagor, Liat , Pery, Ron, Itzkovitz, Shalev

Mayo Clinic

No container title available | February 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.02.22.639181 Get It

Abstract Reconstructing gene expression atlases for human tissues is challenging due to limited access to healthy samples from live donors. Neurologically deceased donors often show ischemic changes, while tissues near diseased regions may have altered gene expression. The liver, with its unique regenerative capacity, allows analysis from live healthy donors (LHDs). Using spatial transcriptomics (Visum, Visium HD and MERFISH), we analyzed 16 liver samples: eight from young LHDs and eight from patients with liver pathology, sampling ‘adjacent normal’ tissue. LHD livers displayed significant gene expression differences from ‘adjacent normal’ tissues. Hepatocytes exhibited marked zonation along the porto-central axis of liver lobules, with key functions pericentrally shifted compared to other mammals. Our atlas identified dynamic programs in early steatotic hepatocytes, showing transitions from lipid uptake in low-lipid regions to insulin hypersensitivity in high-lipid regions. This study presents a spatial gene expression reference for the healthy human liver and insights into hepatocyte adaptations in steatosis.
Executive Summary of a Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D. , Chanques, Gérald , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D , Kho, Michelle E. , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Ross, Chris, Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e701-e710

10.1097/ccm.0000000000006573 | PMID 39982138 Get It

A Focused Update to the Clinical Practice Guidelines for the Prevention and Management of Pain, Anxiety, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU
Lewis, Kimberley , Balas, Michele C. , Stollings, Joanna L. , McNett, Molly , Girard, Timothy D., Chanques, Gérald , Kho, Michelle E. , Weinhouse, Gerald L., Brummel, Nathan E., Duby, Jeremiah J. , Hall-Melnychuk, Erin L., Krupp, Anna , Louzon, Patricia , Tate, Judith A. , Young, Bethany , Jennings, Ron, Hines, Anitra, Ross, Chris, Carayannopoulos, Kallirroi Laiya , Aldrich, Janet , Girard, Timothy D. , Girard, Timothy D , Pandharipande, Pratik , Brummel, Nathan E. , Chlan, Linda L. , Cordoza, Makayla L. , Gélinas, Céline , Aldrich, J. Matthew

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 3 | Pages: e711-e727

10.1097/ccm.0000000000006574 | PMID 39982143 Get It

RATIONALE: Critically ill adults are at risk for a variety of distressing and consequential symptoms both during and after an ICU stay. Management of these symptoms can directly influence outcomes. OBJECTIVES: The objective was to update and expand the Society of Critical Care Medicine’s 2018 Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. PANEL DESIGN: The interprofessional inclusive guidelines task force was composed of 24 individuals including nurses, physicians, pharmacists, physiotherapists, psychologists, and ICU survivors. The task force developed evidence-based recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) approach. Conflict-of-interest policies were strictly followed in all phases of the guidelines, including task force selection and voting. METHODS: The task force focused on five main content areas as they pertain to adult ICU patients: anxiety (new topic), agitation/sedation, delirium, immobility, and sleep disruption. Using the GRADE approach, we conducted a rigorous systematic review for each population, intervention, control, and outcome question to identify the best available evidence, statistically summarized the evidence, assessed the quality of evidence, and then performed the evidence-to-decision framework to formulate recommendations. RESULTS: The task force issued five statements related to the management of anxiety, agitation/sedation, delirium, immobility, and sleep disruption in adults admitted to the ICU. In adult patients admitted to the ICU, the task force issued conditional recommendations to use dexmedetomidine over propofol for sedation, provide enhanced mobilization/rehabilitation over usual mobilization/rehabilitation, and administer melatonin. The task force was unable to issue recommendations on the administration of benzodiazepines to treat anxiety, and the use of antipsychotics to treat delirium. CONCLUSIONS: The guidelines task force provided recommendations for pharmacologic management of agitation/sedation and sleep, and nonpharmacologic management of immobility in critically ill adults. These recommendations are intended for consideration along with the patient’s clinical status.
Concurrent Chest and Abdominal CT: Managing Pitfalls of Splitting Interpretation by Subspecialty
Kelm, Zachary S. , Ron, Eyal D. , Olson, Michael C. , Welle, Christopher L. , Johnson, Tucker F. , Boyum, James H.

Mayo Clinic

RadioGraphics | February 13, 2025 | Volume: 45 | Issue: 3 | Pages: No page available

10.1148/rg.240069 | PMID 39946263 Get It

Dividing the interpretation of concurrently acquired chest and abdominal CT images between two radiologists has advantages, and the potential problems can be mitigated by awareness, defined expectations, and communication.
Experts Achieve Consensus on a Majority of Statements Regarding Ethics, Transparency, Regulation, and Best Practices for the Use of Orthobiologics
Gilat, Ron , Muth, Sarah A. , Hurley, Eoghan T. , Yazdi, Allen A. , Franzia, Chloe H, Shapiro, Shane A. , Cole, Brian J. , Shapiro, Shane , Franzia, Chloe H., Rodeo, Scott A. , Frank, Rachel M , Kon, Elizaveta

Mayo Clinic

Arthroscopy | February 10, 2025 | Volume: 41 | Issue: 9 | Pages: 3611-3621

10.1016/j.arthro.2025.01.062 | PMID 39938667 Get It

Purpose To establish consensus statements via a modified Delphi process about ethics, transparency, regulation, and best practices for the use of orthobiologics in clinical practice for musculoskeletal pathology. Methods A consensus process on the regulation of orthobiologics at the provider level was conducted using a modified Delphi technique. Twenty orthopaedic surgeons, sports medicine physicians, or basic scientists participated. Each participant was a Biologic Association member organization representative and asked to participate because of their active interest in the field of orthobiologics. Levels of consensus were delineated according to the number of votes for each statement: no consensus, <80%; consensus, 80% to 89%; strong consensus, 90% to 99%; unanimous, 100%. Results The 26 consensus statements on orthobiologics resulted in 14 achieving unanimous consensus, 8 achieving strong consensus, 3 achieving consensus, and 1 did not achieve consensus. Overall, 85% of the statements reached either a unanimous or strong consensus. Of the statements regarding communication and transparency, 9 reached unanimous consensus, including information to convey and helpful tools to describe current orthobiologics, persistent misinformation, use of the word “stem cells,” “off‐label” use, and problems with the present regulatory environment. Five statements discussing the regulation of novel orthobiologics achieved unanimous consensus. These statements highlighted research regulation, safety, and suggested improvements to regulatory issues. The statement that did not achieve any consensus was on the regulatory processes that should be in place by an institution providing novel orthobiologic treatments. No statement reached a unanimous agreement on cost or ethical considerations. Conclusions This study successfully identified key consensus statements emphasizing the importance of ethics, transparency, and regulation in the use of orthobiologics, with 85% of statements reaching unanimous or strong consensus. These findings underscore the need for standardized communication, improved regulatory frameworks, and enhanced safety measures while highlighting persistent challenges in addressing cost and ethical considerations. Level of Evidence Level V, expert opinion.
Initial biological classification of Lewy body diseases: No consensus on terminology
Lang, Anthony E. , Adler, Charles H., Berg, Daniela , Outeiro, Tiago F. , Postuma, Ron, Stoessl, A. Jon, Stoessl, A. Jon , Lang, Anthony E , Höglinger, Günter U. , Klein, Christine , Poewe, Werner H

Mayo Clinic

Alzheimer's & Dementia | December 28, 2024 | Volume: 21 | Issue: 2 | Pages: No page available

10.1002/alz.14449 | PMID 39732512 Get It

Impact of a national dementia research consortium: The Canadian Consortium on Neurodegeneration in Aging (CCNA)
Chertkow, Howard , Rockwood, Kenneth, Bartha, Robert , Beaudoin, Camille, Bélanger, Nathalie , Bellec, Pierre , Belleville, Sylvie, Bergman, Howard , Best, Sarah, Bherer, Louis , Borrie, Michael, Camicioli, Richard , Chan, Senny , Crowshoe, Lynden , Cynader, Max S., Das, Samir , Dixon, Roger A., Ducharme, Simon , Fahnestock, Margaret , Feldman, Howard , Ferland, Guylaine , Fogarty, Jennifer, Gauthier, Serge, Greenwood, Carol E., Henri-Bellemare, Charlie, Herrmann, Nathan, Itzhak, Inbal, Jacklin, Kristen , Mackenzie, Ian R. , Masellis, Mario, Maxwell, Colleen J. , McLaurin, JoAnne, Mohades, Zia, Montero‐Odasso, Manuel , Morgan, Debra, Nygaard, Haakon B. , O’Connell, Megan E. , Petersen, Ron, Pilon, Randi, Rajah, Maria Natasha, Rapoport, Mark , Roach, Pamela, Robillard, Julie M. , Rylett, R. Jane , Sadavoy, Joel , Seitz, Dallas , Walker, Jennifer , Whitehead, Victor, Wittich, Walter , Feldman, Howard H , Phillips, Natalie A. , Rockwood, Kenneth J. , Anderson, Nicole D. , Andrew, Melissa Kathryn , Bélanger, Nathalie, Belleville, Sylvie , Bethell, Jennifer , Black, Sandra E. , Carrier, Julie C , Cashman, Neil R. , Cuello, A. Claudio , Dang‐Vu, Thien Thanh , Einstein, Gillian , Evans, Alan Charles , Finger, Elizabeth C. , Fisk, John D. , Fon, Edward A , Gan‐Or, Ziv , Hogan, David B. , Hsiung, Ging‐Yuek Robin , Lanctôt, Krista L. , Lim, Andrew S. P. , McAiney, Carrie A. , McGilton, Katherine S. , McLaurin, JoAnne , Mihailidis, Alex , Morgan, Debra, Naglie, Gary , Rajah, Maria Natasha , Rogaeva, Ekaterina A. , Rosa-Neto, Pedro , George‐Hyslop, Peter St , Smith, Eric Edward , Stefanovic, Bojana , Vedel, Isabelle , Wellington, Cheryl L.

Mayo Clinic

Journal of Alzheimer’s Disease | December 5, 2024 | Volume: 102 | Issue: 3 | Pages: 535-561

10.1177/13872877241290990 | PMID 39636028 Get It

The Canadian Consortium on Neurodegeneration in Aging (CCNA) was created by the Canadian federal government through its health research funding agency, the Canadian Institutes for Health Research (CIHR), in 2014, as a response to the G7 initiative to fight dementia. Two five-year funding cycles (2014–2019; 2019–2024) have occurred following peer review, and a third cycle (Phase 3) has just begun. A unique construct was mandated, consisting of 20 national teams in Phase I and 19 teams in Phase II (with research topics spanning from basic to clinical science to health resource systems) along with cross-cutting programs to support them. Responding to the needs of researchers within the CCNA teams, a unique sample of 1173 deeply phenotyped patients with various forms of dementia was accrued and studied over eight years (COMPASS-ND). In the second phase of funding (2019–2024), a national dementia prevention program (CAN-THUMBS UP) was set up. In a short time, this prevention program became a member of the World Wide FINGERS prevention consortium. In this article, the challenges, successes, and impacts of CCNA in Canada and internationally are discussed. Short-term deliverables have occurred, along with considerable promise of impacts in the longer term. The creation of synergy, networking, capacity building, engagement of people with lived experience, and economies of scale have contributed to the considerable success of CCNA by all measures. CCNA is evidence that an organized “centrally-organized” approach to dementia research can catalyze important progress nationally and yield significant and measurable results.
Artificial intelligence in ophthalmology
Khossravi, Ava S., Chen, Qingyu , Adelman, Ron A.

Mayo Clinic

Current Opinion in Ophthalmology | November 28, 2024 | Volume: 36 | Issue: 1 | Pages: 35-38

10.1097/icu.0000000000001111 | PMID 39607311 Get It

Purpose of review To review role of artificial intelligence in medicine. Recent findings Artificial intelligence is continuing to revolutionize access, diagnosis, personalization of medicine, and treatment in healthcare. As a matter of fact, artificial intelligence contributed to the research that resulted in 2024 Nobel Prizes in physics, chemistry, and economics. We are only at the tip of the iceberg in utilizing the abilities of artificial intelligence in medicine to improve accuracy of diagnoses and to enhance patient outcomes. Artificial intelligence has allowed better image analysis, prediction of progression of disease, personalized treatment plans, incorporations of genomics, and improved efficiency in care and follow-up utilizing home monitoring. In ocular health diagnosis and treatment of diabetic retinopathy, macular degeneration, glaucoma, corneal infections, and ectasia are only a few examples of how the power of artificial intelligence has been harnessed. Even though there are still challenges that need more work in the areas of patient privacy, Health Insurance Portability and Accountability Act (HIPAA) compliance, reliability, and development of regulatory frameworks, artificial intelligence has revolutionized and will continue to revolutionize medicine. Summary Artificial intelligence is enhancing medical diagnosis and treatment, as well as access and prevention. Ocular imaging, visual outcome, optics, intraocular pressure, and data points will continue to see growth it the field of artificial intelligence.
Pembrolizumab ± paricalcitol in metastatic pancreatic cancer postmaximal cytoreduction
Chung, Vincent , Alistar, Angela , Becerra, Carlos, Kasi, Anup , Borazanci, Erkut , Jameson, Gayle , Roe, Denise J. , Wertheim, Betsy C. , Cridebring, Derek , Truitt, Morgan , Downes, Michael , Barrett, Michael T. , Korn, Ron, Lee, Keehoon, Han, Haiyong , Hoff, Daniel D. Von , Wertheim, Betsy C. , Borazanci, Erkut , Chung, Vincent , Lee, Keehoon , Evans, Ronald M.

Mayo Clinic

The Oncologist | November 14, 2024 | Volume: 30 | Issue: 1 | Pages: No page available

10.1093/oncolo/oyae323 | PMID 39846984 Get It

Abstract Lessons learned Intravenous paricalcitol did not improve the efficacy of pembrolizumab, likely related to the short half-life. Background Immunotherapy has limited benefit in the treatment of advanced pancreatic cancer with the tumor microenvironment playing a key role in immune resistance. In preclinical studies, vitamin D receptor (VDR) agonists have been shown to sensitize pancreatic tumors to PD-1 blockade. Methods This was a randomized, double-blinded, placebo-controlled, phase II trial to evaluate pembrolizumab with or without paricalcitol as maintenance therapy for patients with metastatic pancreatic ductal adenocarcinoma (PDAC). Participants were ≥18 years; histologically or cytologically confirmed metastatic PDAC showing no disease progression after frontline systemic therapy, and achieving maximal cytoreduction (eg, with no further antitumor effect), Eastern Cooperative Oncology Group (ECOG) status of 0 or 1; adequate organ function. Study treatment included: pembrolizumab 200 mg IV every 3 weeks and either paricalcitol 25 mcg IV 3 times per week or placebo. The primary objective was to evaluate 6-month progression free survival (PFS). Secondary objectives include evaluating the toxicity of the combination and overall survival (OS). Results There was no significant difference in 6-month PFS, median PFS, median OS, nor treatment-related AEs between the 2 arms. Conclusions and relevance Paricalcitol did not improve the efficacy of pembrolizumab likely related to its short half-life of only 5-7 hours. Microbiome analysis revealed significant difference between long-term (&gt;12 weeks) and short-term (&lt;12 weeks) survival groups across treatment arms. Modulation of the tumor microenvironment will likely require more sustained VDR activity. Trial Registration Clinicaltrials.gov, ID: NCT03331562.
S1193 Improvement in Disease-Related Biomarkers With an Adjuvant Treatment for 180 Days: Results From an Interventional Trial for Patients With Ulcerative Colitis
Turgeon, D. Kim , McClintock, Shannon D., Moraga, Gillian, Harber, Isabelle , McNeely, Molly M. , Varani, James, Aslam, Muhammad N. , Jencks, Kara J. , Stidham, Ryan W , Allen, Ron

Mayo Clinic

American Journal of Gastroenterology | October 24, 2024 | Volume: 119 | Issue: 10S | Pages: S848-S848

10.14309/01.ajg.0001034140.69061.d8 Get It